JP2022553927A - Ｉｌｔ－２阻害剤での癌の処置 - Google Patents

Ｉｌｔ－２阻害剤での癌の処置 Download PDF

Info

Publication number
JP2022553927A
JP2022553927A JP2022522361A JP2022522361A JP2022553927A JP 2022553927 A JP2022553927 A JP 2022553927A JP 2022522361 A JP2022522361 A JP 2022522361A JP 2022522361 A JP2022522361 A JP 2022522361A JP 2022553927 A JP2022553927 A JP 2022553927A
Authority
JP
Japan
Prior art keywords
antibody
ilt2
nkg2a
cells
hla
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2022522361A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022553927A5 (https=
Inventor
ベナック，オリヴィエ
シャントゥー，ステファニー
ペロ，イヴァン
ロッシ，バンジャマン
ヴィオー，ニコラ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innate Pharma SA
Original Assignee
Innate Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innate Pharma SA filed Critical Innate Pharma SA
Publication of JP2022553927A publication Critical patent/JP2022553927A/ja
Publication of JP2022553927A5 publication Critical patent/JP2022553927A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2022522361A 2019-10-14 2020-10-13 Ｉｌｔ－２阻害剤での癌の処置 Withdrawn JP2022553927A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962914595P 2019-10-14 2019-10-14
US62/914,595 2019-10-14
PCT/EP2020/078792 WO2021074157A1 (en) 2019-10-14 2020-10-13 Treatment of cancer with ilt-2 inhibitors

Publications (2)

Publication Number Publication Date
JP2022553927A true JP2022553927A (ja) 2022-12-27
JP2022553927A5 JP2022553927A5 (https=) 2023-10-18

Family

ID=72944114

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022522361A Withdrawn JP2022553927A (ja) 2019-10-14 2020-10-13 Ｉｌｔ－２阻害剤での癌の処置

Country Status (5)

Country Link
US (1) US20240294634A1 (https=)
EP (1) EP4045535A1 (https=)
JP (1) JP2022553927A (https=)
CN (1) CN114901689A (https=)
WO (1) WO2021074157A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7284256B2 (ja) 2019-08-12 2023-05-30 ビオンド バイオロジクス リミテッド Ｉｌｔ２に対する抗体およびその使用
JP2023537396A (ja) 2020-08-12 2023-08-31 ビオンド バイオロジクス リミテッド Ｉｌｔ２に対する抗体およびその使用
WO2024140820A1 (zh) * 2022-12-28 2024-07-04 浙江博锐生物制药有限公司 抗nkg2a抗体及其用途
WO2024260384A1 (en) * 2023-06-20 2024-12-26 Elpiscience (Suzhou) Biopharma, Ltd. Antibodies or antigen-binding fragments binding to lilrb1 and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10329348B2 (en) * 2014-10-23 2019-06-25 Innate Pharma Treatment of cancers using anti-NKG2A agents
SI3405495T1 (sl) * 2016-01-21 2021-08-31 Innate Pharma Nevtralizacija inhibitornih poti v limfocitih
CN111867614A (zh) * 2018-01-18 2020-10-30 艾达奈特公司 抗lilrb抗体及其用途
JP2022516140A (ja) * 2018-12-26 2022-02-24 インネート・ファルマ 白血球免疫グロブリン様受容体２中和抗体

Also Published As

Publication number Publication date
WO2021074157A1 (en) 2021-04-22
EP4045535A1 (en) 2022-08-24
US20240294634A1 (en) 2024-09-05
CN114901689A (zh) 2022-08-12

Similar Documents

Publication Publication Date Title
JP7132981B2 (ja) Ｃｄ７３遮断
US20230235060A1 (en) Neutralization of inhibitory pathways in lymphocytes
CN112513080B (zh) Vista抗原结合分子
CN113330033B (zh) 白细胞免疫球蛋白样受体2中和性抗体
WO2022256563A1 (en) Anti-ccr8 antibodies and uses thereof
KR20190039421A (ko) 항-tigit 항체, 항-pvrig 항체 및 이들의 조합
CN112566935A (zh) 抗ox40抗体和使用方法
JP2022553927A (ja) Ｉｌｔ－２阻害剤での癌の処置
CN114008077A (zh) 抗体和使用方法
EP4151655A1 (en) Anti-cd25 antibodies, antigen-binding fragments thereof, and medical uses thereof
CN114641500A (zh) 使用抗ox40抗体与抗tim3抗体的组合治疗癌症的方法
RU2819204C2 (ru) Антитела, блокирующие cd73
WO2024098980A1 (en) Anti-cd112r antibodies and use thereof
HK40074321A (en) Methods of cancer treatment using anti-ox40 antibodies in combination with anti-tim3 antibodies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231010

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231010

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240502

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20240607